Disorder of glycolysis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:308459
Who is this for?
Show terms as
4Active trials8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Disorder of glycolysis is a group of rare inherited metabolic conditions that affect how your body breaks down glucose (sugar) to produce energy. Glycolysis is one of the most important chemical pathways in the body — it is the process by which cells convert glucose into usable energy. When one of the enzymes involved in this pathway does not work properly due to a genetic change, cells cannot produce energy efficiently. This can affect many organs and tissues, especially those with high energy demands like red blood cells, muscles, and the brain. Symptoms vary depending on which specific enzyme is affected, but common problems include chronic anemia (low red blood cell counts), muscle weakness, exercise intolerance, and sometimes neurological issues. In some forms, red blood cells break down too quickly, a condition called hemolytic anemia. Other forms may primarily affect the muscles, causing cramps, pain, or weakness during physical activity. Treatment is mostly supportive, as there is currently no cure for most glycolysis disorders. Management may include blood transfusions for severe anemia, careful monitoring of energy levels, dietary adjustments, and avoidance of triggers that worsen symptoms. Some patients benefit from supplements or specific dietary strategies. Early diagnosis and ongoing care from a team of specialists can help improve quality of life. Well-known specific disorders within this group include pyruvate kinase deficiency, phosphofructokinase deficiency (Tarui disease), and glucose-6-phosphate isomerase deficiency, among others.

Key symptoms:

Chronic anemia (low red blood cell count)Yellowing of the skin and eyes (jaundice)Fatigue and low energyMuscle weaknessMuscle cramps or pain during exerciseExercise intoleranceEnlarged spleenDark-colored urineGallstones at a young ageShortness of breathPale skinDelayed growth in childrenNeurological problems in some formsRecurrent infections in some forms

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

4 events
Jun 2022A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period

Agios Pharmaceuticals, Inc. — PHASE3

TrialACTIVE NOT RECRUITING
Jun 2022A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period

Agios Pharmaceuticals, Inc. — PHASE3

TrialACTIVE NOT RECRUITING
Feb 2022Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms

Massachusetts General Hospital

TrialACTIVE NOT RECRUITING
Apr 2018Pyruvate Kinase Deficiency Global Longitudinal Registry

Agios Pharmaceuticals, Inc.

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Disorder of glycolysis.

4 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

4 recruitingView all trials with filters →
Phase 32 trials
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period
Phase 3
Active
PI: Medical Affairs (Agios Pharmaceuticals, Inc.) · Sites: Phoenix, Arizona; Palo Alto, California +20 more · Age: 117 yrs
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period
Phase 3
Active
PI: Medical Affairs (Agios Pharmaceuticals, Inc.) · Sites: Palo Alto, California; Aurora, Colorado +17 more · Age: 117 yrs
Other2 trials
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
Active
PI: Hanny Al-Samkari, MD (Massachusetts General Hospital) · Sites: Boston, Massachusetts · Age: 1899 yrs
Pyruvate Kinase Deficiency Global Longitudinal Registry
Active
PI: Eva Gallagher, VP, Medical Affairs (Agios Pharmaceuticals, Inc.) · Sites: Phoenix, Arizona; Little Rock, Arkansas +50 more

No specialists are currently listed for Disorder of glycolysis.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Disorder of glycolysis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Disorder of glycolysisForum →

No community posts yet. Be the first to share your experience with Disorder of glycolysis.

Start the conversation →

Latest news about Disorder of glycolysis

No recent news articles for Disorder of glycolysis.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Which specific enzyme or gene is affected in my case, and what does that mean for my symptoms?,Will I or my child need regular blood transfusions, and if so, how will iron overload be managed?,Is splenectomy recommended, and what are the risks and benefits?,Are there any new or emerging treatments, such as mitapivat or gene therapy, that might apply to my specific type?,What physical activities are safe, and which should be avoided?,Should other family members be tested for this condition?,What warning signs should prompt me to seek emergency care?

Common questions about Disorder of glycolysis

What is Disorder of glycolysis?

Disorder of glycolysis is a group of rare inherited metabolic conditions that affect how your body breaks down glucose (sugar) to produce energy. Glycolysis is one of the most important chemical pathways in the body — it is the process by which cells convert glucose into usable energy. When one of the enzymes involved in this pathway does not work properly due to a genetic change, cells cannot produce energy efficiently. This can affect many organs and tissues, especially those with high energy demands like red blood cells, muscles, and the brain. Symptoms vary depending on which specific enz

How is Disorder of glycolysis inherited?

Disorder of glycolysis follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Disorder of glycolysis?

Yes — 4 recruiting clinical trials are currently listed for Disorder of glycolysis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.